FILING ANALYSIS · FRIDAY, OCTOBER 30
Aurinia Pharmaceuticals Inc. AUPH — 8-K: Results of Operations and Financial Condition
positive
Aurinia Pharmaceuticals Inc. reported a 19% increase in total revenue for the nine months ended September 30, 2026, and raised its total revenue guidance for 2026 from $315-325 million to $325-330 million, driven by strong sales of its lupus nephritis treatment LUPKYNIS.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →